Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Sells $71,390.70 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREGet Free Report) Director Corazon (Corsee) D. Sanders sold 1,737 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, June 10th. The shares were sold at an average price of $41.10, for a total transaction of $71,390.70. Following the transaction, the director now owns 7,248 shares in the company, valued at approximately $297,892.80. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Ultragenyx Pharmaceutical Trading Up 1.4 %

RARE stock opened at $41.97 on Tuesday. The stock’s 50 day simple moving average is $43.16 and its 200 day simple moving average is $45.11. Ultragenyx Pharmaceutical Inc. has a 12-month low of $31.52 and a 12-month high of $54.56. The firm has a market cap of $3.49 billion, a P/E ratio of -5.23 and a beta of 0.60.

Ultragenyx Pharmaceutical (NASDAQ:RAREGet Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31). Ultragenyx Pharmaceutical had a negative return on equity of 425.63% and a negative net margin of 138.58%. The business had revenue of $108.83 million during the quarter, compared to the consensus estimate of $116.03 million. During the same quarter in the previous year, the business posted ($2.33) earnings per share. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. On average, research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.49 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on RARE. Cantor Fitzgerald raised their price objective on Ultragenyx Pharmaceutical from $107.00 to $115.00 and gave the company an “overweight” rating in a research report on Friday, May 31st. Wedbush raised their target price on Ultragenyx Pharmaceutical from $47.00 to $48.00 and gave the company a “neutral” rating in a report on Friday, May 31st. JPMorgan Chase & Co. upped their price target on Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, March 18th. Royal Bank of Canada began coverage on shares of Ultragenyx Pharmaceutical in a research report on Monday, April 22nd. They issued an “outperform” rating and a $77.00 price objective for the company. Finally, Robert W. Baird boosted their target price on shares of Ultragenyx Pharmaceutical from $68.00 to $72.00 and gave the stock an “outperform” rating in a research report on Friday, May 31st. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $86.71.

View Our Latest Report on RARE

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Headlands Technologies LLC bought a new position in Ultragenyx Pharmaceutical in the 1st quarter worth approximately $28,000. UMB Bank n.a. grew its stake in shares of Ultragenyx Pharmaceutical by 118.8% in the fourth quarter. UMB Bank n.a. now owns 606 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 329 shares in the last quarter. Covestor Ltd increased its holdings in shares of Ultragenyx Pharmaceutical by 392.1% during the third quarter. Covestor Ltd now owns 748 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 596 shares during the period. GAMMA Investing LLC raised its stake in shares of Ultragenyx Pharmaceutical by 622.3% during the first quarter. GAMMA Investing LLC now owns 1,004 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 865 shares in the last quarter. Finally, Van ECK Associates Corp lifted its holdings in Ultragenyx Pharmaceutical by 34.0% in the fourth quarter. Van ECK Associates Corp now owns 1,578 shares of the biopharmaceutical company’s stock worth $75,000 after purchasing an additional 400 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

(Get Free Report)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Recommended Stories

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.